新方案令“最毒乳腺癌”患者生存率显著提升，复旦肿瘤成果登《英国医学杂志》

Core Insights - A recent clinical study led by Professor Shao Zhimin from Fudan University Shanghai Cancer Center published in the British Medical Journal demonstrates a significant improvement in the treatment of high-risk early-stage triple-negative breast cancer (TNBC) patients through the addition of carboplatin to standard chemotherapy, achieving a 3-year disease-free survival rate of 92.3% and reducing recurrence risk by 36% compared to the control group [4][11]. Group 1: Clinical Study Overview - The study involved 808 high-risk early-stage TNBC patients, randomized into a trial group receiving intensified chemotherapy with carboplatin and a control group receiving standard treatment [10]. - High-risk patients were defined as those with lymph node metastasis or a high tumor cell proliferation index (Ki-67≥50%) [6]. Group 2: Treatment Efficacy - The trial group showed a 3-year disease-free survival rate of 92.3%, compared to 85.8% in the control group, representing a 6.5 percentage point absolute increase [11]. - The overall survival rate for the trial group reached 98.0%, indicating a significant advantage in key efficacy metrics [11]. Group 3: Safety and Side Effects - While the trial group experienced a slight increase in hematological toxicities such as neutropenia and anemia, these side effects were within expected ranges and deemed manageable [11]. - The study's findings support the safety and feasibility of the carboplatin-enhanced treatment regimen, laying a solid foundation for clinical application [11]. Group 4: Implications for Future Treatment - This research marks a shift from homogeneous chemotherapy to risk-based intensified treatment for early-stage TNBC, symbolizing a new era in precision medicine [12]. - The findings suggest a transition in standard treatment protocols from the current "anthracycline + taxane" regimen to a new combination including "anthracycline + taxane + platinum" [12].